Immunetrics’ disease models span across acute inflammation, chronic autoimmune conditions, and immuno-oncology.

Immunetrics has developed a suite of models which have been trained to publically available data and are constantly evolving to support new research outcomes. These models can be used in their current state, extended and trained to richer, proprietary data sets, or otherwise customized to meet specific needs.


Autoimmune Disease Models

Immunetrics’ models include both explicitly represented biological species (e.g. specific cell types and proteins) as well as abstract variables that represent aggregate behavior of a set of biological species (e.g. higher-level disease physiology). These species form a network of known mechanisms that are modulated by therapies and link to clinical endpoints for prediction of clinical trial results.

 

Rheumatoid Arthritis (RA)

Model supports inadequate response to standard of care (methotrexate) and TNF inhibitors.

Key Model OutputsSupported Therapies
Swollen/Tender Joint Count (SJC28/TJC28)
ACR20/50/70
DAS28(3)-CRP/ESR
Low Disease Activity / Remission
Cell Counts
Cytokines and Biomarkers (including CRP & ESR)
Methotrexate
Corticosteroids
JAK Inhibitors (Baricitinib, Tofacitinib, Upadacitinib)
Anti-TNF (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab)
Anti-IL6 (Tocilizumab)
Anti-T and B cell therapies (Abatacept, Rituximab)
BTK inhibitors (Fenebrutinib, Elsubrutinib)

PSORIATIC ARTHRITIS (PsA)

Key Model OutputsSupported Therapies
Swollen/Tender Joint Count (SJC28/TJC28)
ACR20/50/70
DAS28(3)-CRP/ESR
PASI50/75/90/100
Cell Counts
Cytokines and Biomarkers
Methotrexate
Corticosteroids
T cell inhibitor (Abatacept)
TNF inhibitors (Adalimumab, Etanercept, Golimumab, Certolizumab Pegol)
anti-IL17 (Ixekizumab, Secukinumab)
anti-IL12/23 (Ustekinumab)
anti-IL23 (Guselkumab and Risankizumab)
Jak inhibitors (Tofacitinib and Upadacitinib)
Tyk2 inhibitors (Deucravacitinib)

Psoriasis (PsO)

Key Model OutputsSupported Therapies
BSA
PASI50/75/90/100
Cell Counts
Cytokines and Biomarkers
anti-IL17 (Ixekizumab and Secukinumab)
anti-IL12/23 (Ustekinumab)
anti-IL23 (Guselkumab and Risankizumab)
Jak inhibitor (Tofacitinib)
Tyk2 inhibitor (Deucravacitinib)

Atopic Dermatitis (AD)

Key Model OutputsSupported Therapies
EASI
SCORAD
EASI75
IGA Responder
Cell Counts
Cytokines and Biomarkers
Corticosteroids
Calcineurin Inhibitors
JAK Inhibitors (abrocitinib, baricitinib, upadacitinib)
anti-IL13 (tralokinumab)
anti-IL4r (dupilumab)

Ulcerative Colitis (UC)

Model supports local and central endoscopic assessments, Full and Partial Mayo Score, and Induction and Maintenance trial phases.

Key Model OutputsSupported Therapies
Full / Partial Mayo score
Response / Remission
Mucosal healing
Cytokines and Biomarkers
Corticosteroids
5ASA
TNF inhibitors (Adalimumab, Golimumab, Infliximab)
JAK inhibitors (Filgotinib, Tofacitinib, Upadacitinib)
S1P receptor antagonists (Ozanimod)
anti-chemotaxis drugs (Vedolizumab, Ontamalimab, Etrolizumab)
anti-IL12/23 (Ustekinumab)
anti-IL23 (Guselkumab, Mirikizumab)

Systemic Lupus Erythematosus (SLE)

Model requires client supplied individual patient data to train clinical measure outputs.

Key Model OutputsSupported Therapies
CLASI
CLASI Responder
Swollen Joint Count (SJC)
Steroid Taper
Cytokines and Biomarkers
Individual patient data is required to support:
SRI4
BICLA
SLEDAI
Low Disease Activity
Corticosteroids (including tapering protocols)
anti-BDCA2 (Litifilimab)
anti-IFNa (Sifalimumab, Anifrolumab)
anti-BAFF (Belimumab, Tabalumab)
anti-IL12/23 (Ustekinumab)
JAK inhibitor (Baricitinib)

Crohn’s Disease (CD)

Model requires client supplied individual patient data to train clinical measure outputs.

Key Model OutputsSupported Therapies
CDEIS
SES-CD
CDAI
CDAI-70/100
Remission
Response
Mucosal Healing
Stool Frequency
Cytokines and Biomarkers
Cell counts
JAK Inhibitors (upadacitinib, filgotinib, tofacitinib)
anti-TNF (adalimumab, infliximab, certolizumab)
anti-IL12/23 (ustekinumab)
anti-IL17 (brodalumab, secukinumab)
anti-IL23 (risankizumab)
anti cell trafficking therapies (vedolizumab, anti-MadCAM)
anti T cell therapies (abatacept)


Immuno-Oncology Models

Acute Myeloid Leukemia (AML)

For this model, response measures are based on blast counts.

Key Model OutputsSupported Therapies
Best Overall Response (BOR):
· Complete Response (CR)
· Partial Response (PR)
· Stable Disease (SD)
· Partial Disease (PD)
Response vs Non-response
Minimal Residual Disease (MRD = < 0.1% Blasts)
Death
Duration of Response (DoR)
Relapse
Disease-specific Biomarkers: 
· Percent Blasts (Bone marrow and blood)
Hypomethylating Agents (azacitidine)
Chemotherapies (cytarabine)
BCL-2 inhibitor (venetoclax)
Monoclonal antibodies (e.g. anti-CD47) 

Multiple Myeloma (MM)

For this model, the response measures are based on the percent change in M protein, FLCs, and MM clones.  The Antibody Drug Conjugates and NK Cell Engager implementations requires client supplied data

Key Model OutputsSupported Therapies
Best Overall Response (BOR):
· Complete Response (CR)
· Partial Response (PR)
· Stable Disease (SD)
· Partial Disease (PD)
Overall Response Rate (ORR)
Time to Response (TTR)
Duration of Response (DoR)
Disease Specific Biomarkers:
· Soluble B-Cell Maturation Antigen (sBCMA)
· M-Protein
· Soluble Free Light Chain (sFLC)
Immunomodulatory Drugs (IMiDs)
Antibody-Drug Conjugates (ADCs)
Immune Cell Engagers (NK and T cell) 
Monoclonal Antibodies (Daratumumab, Elotuzumab)
Chimeric Antigen Receptor T-cell Therapies (CAR T)
Steroids (Dexamethasone) 

Non-Small Cell Lung Cancer (NSCLC)

Key Model OutputsSupported Therapies
Percent change in Tumor Diameter
Best Overall Response (BOR)
Progressive Disease (PD)
Stable Disease (SD)
Responders (RR)
Monoclonal Antibodies:
· anti-PD-1 (Nivolumab and Pembrolizumab)
· anti-CTLA-4 (Ipilimumab)
· anti-PDL1 (Atezolizumab)
· TLR9 agonist (PF-3512676)
· Interferon alfa-2a (Roferon A)
· Epacadostat
Chemotherapies:
· alkylating agents (Carboplatin)
· cytoskeletal drugs (Paclitaxel)
· Gemcitabine
· Pemetrexed

Diffuse Large B-Cell lymphoma (dlbcl)

Key Model OutputsSupported Therapies
Complete Responder (CR)
Partial Responder (PR)
Tumor Cell Number
Chimeric Antigen Receptor T cell Therapies (CAR-T):
· ricAxiabtagene ciloleucel (axi-cel)
· tisgenlecleucel (CTL019)
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) 
Immunomodulatory Drugs (IMiDs) (Lenalidomide)